Wedbush restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research note published on Thursday, AnalystRatings.com reports. Wedbush currently has a $25.00 price objective on the biotechnology company’s stock.
A number of other equities analysts also recently weighed in on the stock. ValuEngine raised shares of XOMA from a hold rating to a buy rating in a research note on Tuesday, July 2nd. HC Wainwright set a $30.00 target price on shares of XOMA and gave the company a buy rating in a research note on Friday, June 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $23.75.
Shares of XOMA opened at $17.29 on Thursday. The company has a quick ratio of 7.20, a current ratio of 7.20 and a debt-to-equity ratio of 1.13. XOMA has a one year low of $11.02 and a one year high of $25.75. The business has a 50-day moving average of $17.17.
XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.33. XOMA had a negative net margin of 48.62% and a negative return on equity of 51.66%. The business had revenue of $8.13 million during the quarter, compared to the consensus estimate of $3.23 million. Sell-side analysts predict that XOMA will post -1.09 EPS for the current fiscal year.
In other XOMA news, insider Value Fund L. P. Biotechnology bought 27,913 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was acquired at an average price of $14.63 per share, with a total value of $408,367.19. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bvf Partners L. P/Il bought 3,797 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $14.36 per share, with a total value of $54,524.92. The disclosure for this purchase can be found here. Insiders have acquired 42,010 shares of company stock valued at $612,963 in the last ninety days. Insiders own 9.89% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. California Public Employees Retirement System lifted its stake in XOMA by 11.5% in the fourth quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,220 shares during the last quarter. BlackRock Inc. lifted its stake in XOMA by 12.4% in the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock valued at $6,434,000 after purchasing an additional 56,130 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in XOMA by 19.0% in the fourth quarter. Bank of New York Mellon Corp now owns 60,173 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 9,613 shares during the last quarter. Northern Trust Corp lifted its stake in XOMA by 13.7% in the fourth quarter. Northern Trust Corp now owns 83,470 shares of the biotechnology company’s stock valued at $1,056,000 after purchasing an additional 10,072 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in XOMA by 9.9% in the fourth quarter. Two Sigma Advisers LP now owns 32,195 shares of the biotechnology company’s stock valued at $407,000 after purchasing an additional 2,905 shares during the last quarter. 47.85% of the stock is owned by institutional investors and hedge funds.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
See Also: Options Trading
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.